Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.

Abstract

Two studies comparing the cost-effectiveness of irbesartan to similar blood pressure control with standard antihypertensive medications (excluding angiotensin-converting enzyme inhibitors and other angiotensin receptor blockers) in treatment of patients with hypertension, type 2 diabetes, and microalbuminuria have been published to date; one in a United… (More)

Topics

  • Presentations referencing similar topics